<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58789">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016534</url>
  </required_header>
  <id_info>
    <org_study_id>20130111</org_study_id>
    <secondary_id>2013-001277-24</secondary_id>
    <nct_id>NCT02016534</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors</brief_title>
  <official_title>A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <authority>Unites States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Chile: Instituto de Salud Pública de Chile</authority>
    <authority>Peru: Instituto Nacional de Salud</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre Phase 2 study. The study will evaluate the activity and safety of AMG
      337 in patients who have MET amplified gastric, gastroesophageal junction or esophageal
      adenocarcinoma or other MET amplified solid tumors. The study is designed to estimate the
      objective response rate of AMG 337 by tumor type.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2, multicenter, single arm, 2 cohort study to assess the safety, efficacy
      and pharmacokinetics of AMG 337 in MET amplified Gastric/esophageal adenocarcinoma or other
      solid tumors. Approximately 140 subjects will be enrolled to either Cohort 1 (subjects with
      MET amplified G/E adenocarcinoma with measurable tumor) or Cohort 2 (subjects with MET
      amplified solid tumors with measurable tumor/up to 10 subjects with MET amplified G/E
      adenocarcinoma with non-measurable tumor/up to 10 subjects who have received prior MET
      antibody therapy). All subjects will self-administer AMG 337 300 mg daily until disease
      progression or other protocol specified end of treatment criteria is met.

      Tumor tissue, biomarkers, Pharmacokinetics and Patient reported Outcomes will all be
      assessed.

      Tumor assessment by RECIST 1.1 will be followed during study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1)</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine antitumor activity of AMG 337 in subjects with MET amplified G/GEJ/E adenocarcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (cohort 1 and subjects with measurable disease at baseline in cohort 2)</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (Cohort 1 and subjects with measurable disease at baseline in cohort 2)</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events and significant laboratory abnormalities</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AMG 337 exposure and dose intensity</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Including, but not limited to, minimum (trough) concentrations at pre-dose times, maximum concentrations (C max), the time of C max (t max), and area under the plasma concentration - time curve (AUC).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO) Health realated quality of life (HRQoL)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the impact of AMG 337 on health-related quality of life (HRQoL) in subjects with MET amplified G/GEJ/E adenocarcinoma (Cohort 1 only).</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor tissue and circulating serum biomarkers</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessed at baseline. Circulating tumor cells (CTC) and circulating serum biomarkers will also be assessed at baseline and during study treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Prediction of response rates to AMG 337 by analysing tumor DNA for MET pathway-related genes</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To analyse tumor DNA samples for MET pathway-related genes (and other genes based on emerging data) that may predict response to AMG 337</description>
  </other_outcome>
  <other_outcome>
    <measure>Response to AMG 337 and MET amplification, expression or presence of mutation in tumor specimens</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Explore whether the level of MET amplification, expression, or presence of mutation in tumor specimens correlates with response to AMG 337.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 337</intervention_name>
    <description>AMG 337 300mg orally daily.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to daily self-administer AMG 337 orally as a whole capsule

          -  Male or female 18 years of age or over.

          -  Pathologically confirmed advanced G/GEJ/E adenocarcinoma (Cohort 1) or other solid
             tumor (Cohort 2) for which subject has received prior therapy for advanced disease,
             for which no standard therapy exists, or subject refuses standard therapy

          -  Tumor MET amplified by protocol-specified centralized testing.

          -  Measurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects
             with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per
             RECIST v1.1

          -  (ECOG) Performance Status of 0 or 1

        Exclusion Criteria:

          -  Known central nervous system metastases

          -  Candidate for curative surgery or definitive chemoradiation

          -  Peripheral edema &gt; grade 1

          -  Persistent gastric outlet obstruction, complete dysphagia or are dependent upon
             jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion
             of the Investigator may influence drug absorption

          -  Acute Hepatitis B. Chronic Hepatitis B eligible if condition is stable and, in the
             opinion of the investigator or Amgen physician, if consulted, would not pose a risk
             to subject safety

          -  Detectable Hepatitis C virus (indicative of active Hepatitis C)

          -  Currently receiving any anti-tumor treatments, or less than 14 days prior to
             enrollment since ending anti-tumor treatment

          -  Prior treatment with small molecule inhibitors of the MET pathway.

        Other protocol defined inclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bentleigh East</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rozzano MI</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Konin</city>
        <zip>62-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucía</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MET Amplified Gastric / Gastroesophageal Junction / Esophageal Adenocarcinoma, or other solid tumors.</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
